cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Rachmat Hidayat
Contact Email
dr.rachmat.hidayat@gmail.com
Phone
+6288225053819
Journal Mail Official
eureka.herba.indonesia@gmail.com
Editorial Address
Dr. Moh Ali street Palembang South Sumatera Indonesia
Location
Kota palembang,
Sumatera selatan
INDONESIA
Eureka Herba Indonesia
Published by HM Publisher
ISSN : -     EISSN : 27465152     DOI : https://doi.org/10.37275/ehi.v1i1.1
Core Subject : Health,
Medicine & Pharmacology
Eureka Herba Indonesia (EHI) is peer review scientific journal that focused on reserach in exploration potential Herba of Indonesia for enhancing healthy. EHI focused on : 1. Medicinal Plants. 2. Efficacy of Herba Study. 3. Safety of Herba Study. 4. Animals that potential for developing as healthy products. 5. Minerals that potential for developing as healthy products.
Arjuna Subject : Kedokteran - Kedokteran Komplemen dan Alternatif
Articles 106 Documents
 7   8   9   10   11 
Curcuminoids for the Management of Diabetic Macular Edema: A Meta-Analysis Evaluating Effects on Central Macular Thickness and Visual Acuity Ramzi Amin; Mandy Putriyudi
Eureka Herba Indonesia Vol. 5 No. 2 (2024): Eureka Herba Indonesia
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/ehi.v5i2.127

Abstract

Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients, driven primarily by inflammation, oxidative stress, and increased vascular permeability. Current standard therapies, while effective, have limitations. Curcuminoids, derived from Curcuma longa, possess potent anti-inflammatory, antioxidant, and anti-angiogenic properties, suggesting potential therapeutic value in DME. However, clinical evidence requires synthesis. This meta-analysis aimed to evaluate the efficacy of curcuminoid supplementation on Central Macular Thickness (CMT) and Best-Corrected Visual Acuity (BCVA) in patients with DME. A literature search was conducted in PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases from January 1st, 2013, to December 31st, 2023. We included randomized controlled trials (RCTs) and controlled clinical trials comparing curcuminoid supplementation (as adjunct or monotherapy) against placebo or standard care alone in patients with DME, reporting CMT and/or BCVA outcomes. Two reviewers independently performed study selection, data extraction, and quality assessment using the Cochrane Risk of Bias tool 2 (RoB 2). Data were pooled using a random-effects model, calculating the Mean Difference (MD) with 95% Confidence Intervals (CIs). Heterogeneity was assessed using the I² statistic. Six studies (comprising 388 patients) met the inclusion criteria. The included studies varied in curcuminoid formulations, dosages (ranging from 80 mg to 1500 mg daily), and follow-up durations (3 to 12 months). The overall risk of bias across studies was mixed, with some concerns primarily related to blinding and outcome reporting in several trials. Meta-analysis demonstrated that curcuminoid supplementation was associated with a statistically significant reduction in CMT compared to control groups (MD = -28.54 μm; 95% CI [-45.11, -11.97]; p = 0.0007). Moderate heterogeneity was observed (I² = 62%, p = 0.02). For BCVA (LogMAR), curcuminoid supplementation showed a trend towards improvement, but the result was not statistically significant (MD = -0.04 LogMAR; 95% CI [-0.09, 0.01]; p = 0.11). Heterogeneity for BCVA was low (I² = 15%, p = 0.31). In conclusion, adjunctive curcuminoid supplementation may contribute to a modest but statistically significant reduction in CMT in patients with DME. No statistically significant improvement in BCVA was confirmed, although a favourable trend was observed. Significant heterogeneity in CMT results and methodological limitations in primary studies necessitate cautious interpretation. Larger, well-designed RCTs with standardized, bioavailable curcuminoid formulations and longer follow-up are warranted to definitively establish the clinical role of curcuminoids in DME management.
Phytotherapeutic Interventions Targeting Microvascular Dysfunction in Early Non-Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Effects on Retinal Perfusion and Function Ramzi Amin; Muhammad Baqir
Eureka Herba Indonesia Vol. 6 No. 1 (2025): Eureka Herba Indonesia
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/ehi.v6i1.129

Abstract

Microvascular dysfunction, encompassing impaired perfusion and subsequent functional deficits, is a hallmark of early non-proliferative diabetic retinopathy (NPDR). Phytotherapeutic agents, with their potential antioxidant, anti-inflammatory, and vasculoprotective properties, have emerged as candidate interventions. However, synthesized evidence regarding their specific impact on retinal perfusion and function in early NPDR remains limited. This systematic review and meta-analysis aimed to evaluate the efficacy of phytotherapeutic interventions on quantitative measures of retinal perfusion and visual function in patients with early NPDR. A systematic literature search was conducted in PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomized controlled trials (RCTs) published between January 2013 and December 2024. Studies evaluating any phytotherapeutic intervention versus placebo or standard care in patients with early NPDR, reporting outcomes related to retinal perfusion (including Foveal Avascular Zone [FAZ] area, capillary density via Optical Coherence Tomography Angiography [OCT-A]) or retinal function (including Best-Corrected Visual Acuity [BCVA], Contrast Sensitivity [CS], electroretinogram [ERG] parameters) were considered. Data from seven RCTs meeting eligibility criteria were analyzed. Data extraction and risk of bias assessment (Cochrane RoB 2 tool) were performed. Meta-analyses using a random-effects model were conducted for key outcomes, calculating Mean Differences (MD) or Standardized Mean Differences (SMD) with 95% Confidence Intervals (CIs). Heterogeneity was assessed using the I² statistic. Seven RCTs (total N=585 patients) were included. The interventions evaluated included Ginkgo biloba, Bilberry extract, Curcumin, Saffron, Pycnogenol, Mirtogenol, and a standardized Traditional Chinese Medicine (TCM) formula. Risk of bias across the studies varied, with concerns primarily in blinding and outcome measurement domains in some trials. Meta-analysis indicated that phytotherapeutic interventions were associated with a statistically significant improvement in retinal perfusion markers compared to control. This included a reduction in FAZ area (MD: -0.04 mm², 95% CI [-0.06, -0.02], P<0.001; I²=58%) and an increase in parafoveal superficial capillary density (MD: +1.85 %, 95% CI [+1.10, +2.60], P<0.001; I²=65%). Functional improvements were also observed, including BCVA (MD: -0.03 logMAR, 95% CI [-0.05, -0.01], P=0.005; I²=35%) and contrast sensitivity (SMD: 0.35, 95% CI [0.15, 0.55], P<0.001; I²=48%). Safety data suggested no significant increase in major adverse events compared to control groups (Risk Ratio: 1.12, 95% CI [0.75, 1.68], P=0.58; I²=0%). In conclusion, this systematic review and meta-analysis found that phytotherapeutic interventions improve retinal microvascular perfusion and associated visual function in patients with early NPDR, with an acceptable safety profile. These findings support the potential role of specific phytotherapies as adjunctive treatments in managing early diabetic microvascular changes. Further large-scale trials are warranted to confirm these benefits and explore long-term outcomes.
Modulation of the Cognition-Sleep Nexus in Subjective Cognitive Decline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial of a Standardized Cordyceps militaris Extract Vita Amanda; Daphne Marshall; Zahra Amir; Husin Sastranagara; Danniel Hilman Maulana; Karina Chandra; Fachrudin Sani
Eureka Herba Indonesia Vol. 6 No. 2 (2025): Eureka Herba Indonesia
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/ehi.v6i2.130

Abstract

Subjective cognitive decline (SCD) and sleep disturbance form a vicious cycle, accelerating neurodegeneration. Cordyceps militaris (CM), a traditional medicinal fungus rich in nucleosides, possesses potent neuroprotective and adenosinergic (sleep-promoting) properties. We investigated the efficacy of a standardized CM extract on this cognition-sleep nexus in adults with SCD. This 12-week, single-center, randomized, double-blind, placebo-controlled, parallel-group trial was conducted in Palembang, Indonesia. We randomized 120 adults (aged 45-65) with SCD to receive 300 mg/day of a standardized CM mycelial extract (3% cordycepin) or a matching placebo. The primary outcome was the change from baseline in the Montreal Cognitive Assessment-Indonesian (MoCA-INA) score. Key secondary outcomes (Bonferroni-corrected) were the Pittsburgh Sleep Quality Index (PSQI), Rey Auditory Verbal Learning Test (RAVLT) Delayed Recall, and polysomnography (PSG)-derived Sleep Efficiency (SE). Analyses were performed on the Intention-to-Treat (ITT) population (N=120) using a Linear Mixed-Effects Model (LMM). The LMM analysis revealed a significant group-by-time interaction for the primary outcome, MoCA-INA (Adjusted Mean Difference [AMD]: +1.95 [95% CI: 1.10, 2.80], p < 0.001). The CM group also showed significant improvements in all three key secondary outcomes: PSQI (AMD: -2.90 [95% CI: -3.81, -1.99], p < 0.001), RAVLT Delayed Recall (AMD: +2.15 [95% CI: 1.30, 3.00], p < 0.001), and Sleep Efficiency (AMD: +5.8% [95% CI: 3.1, 8.5], p < 0.001). After FDR correction, significant benefits were also seen for processing speed, %REM sleep, and serum BDNF and hs-CRP. The intervention was well-tolerated. In conclusion, twelve weeks of supplementation with a standardized C. militaris extract significantly improved cognitive function, episodic memory, and both subjective and objective sleep in adults with SCD. These benefits were associated with enhanced neuroplasticity and reduced systemic inflammation, supporting its potential as a multi-target, disease-modifying intervention for this at-risk population.
Curcumin Reverses Cisplatin Resistance in NSCLC via Transcriptional Suppression of ABCB1 and Functional Inhibition of P-glycoprotein: A Mechanistic and Synergistic Analysis Khairiel Anwar; Eduardo Michael Perez; Febria Suryani; Franklin Shane
Eureka Herba Indonesia Vol. 6 No. 1 (2025): Eureka Herba Indonesia
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/ehi.v6i1.131

Abstract

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality globally. The efficacy of Cisplatin (DDP), a first-line chemotherapeutic, is frequently compromised by multidrug resistance (MDR), primarily driven by the overexpression of the ATP-binding cassette transporter P-glycoprotein (P-gp/ABCB1). Curcumin, a polyphenol with pleiotropic pharmacological effects, has shown potential as a chemosensitizer. This study aimed to rigorously quantify the synergistic interaction between Curcumin and Cisplatin and elucidate whether the reversal of resistance is mediated through functional blockade or genetic suppression of ABCB1. We utilized the human NSCLC cell line A549 and its stable, authenticated DDP-resistant counterpart (A549/DDP). Cytotoxicity was assessed using the CCK-8 assay with strict vehicle controls. Drug synergy was quantified using the Chou-Talalay Combination Index (CI) method. P-gp efflux function was evaluated by Rhodamine 123 (Rh123) accumulation, while apoptosis was analyzed via Annexin V-FITC/PI flow cytometry. The expression levels of P-gp and ABCB1 mRNA were determined by Western blotting and RT-qPCR, adhering to MIQE guidelines. A549/DDP cells exhibited a robust resistance phenotype (Resistance Index: 13.4). Co-treatment with non-toxic concentrations of Curcumin (20 μM) significantly reduced the IC50 of Cisplatin from 56.42 μM to 6.85 μM (p < 0.001), yielding a Reversal Fold of 8.2. The Combination Index was 0.45, indicating strong synergism. Curcumin treatment blocked P-gp-mediated efflux and, critically, downregulated ABCB1 mRNA by 72% and protein expression in a dose-dependent manner. This dual mechanism restored apoptotic sensitivity, increasing rates from 12.5% to 46.8%. In conclusion, curcumin effectively reverses Cisplatin resistance in NSCLC through a dual mechanism: immediate functional inhibition of the P-gp pump and delayed transcriptional repression of ABCB1. These findings support the development of Curcumin-based adjuvant therapies to overcome MDR.
Comparative Efficacy and Acute Tolerability of a Standardized Withania somnifera Root Extract Versus Sertraline in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Non-Inferiority Trial Ni Made Nova Indriani; Suyong Zhou; Riri Arisanty Syafril Lubis; Jason Willmare
Eureka Herba Indonesia Vol. 6 No. 1 (2025): Eureka Herba Indonesia
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/ehi.v6i1.132

Abstract

Generalized anxiety disorder (GAD) represents a significant psychiatric burden, characterized by chronic hyperarousal and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. While selective serotonin reuptake inhibitors (SSRIs) like Sertraline are the standard of care, their utility is often compromised by delayed onset and adverse effects, specifically sexual dysfunction. Withania somnifera (Ashwagandha) acts as a GABA-mimetic and adaptogen, yet rigorous head-to-head comparisons against pharmaceutical controls are rare. We conducted an 8-week, randomized, double-blind, placebo-controlled trial involving 150 adults with DSM-5 diagnosed GAD. Participants were randomized (1:1:1) to receive High-Concentration Ashwagandha Root Extract (600 mg/day, standardized to >5% withanolides), Sertraline (50 mg/day), or Placebo. Blinding was maintained using mint-scented desiccants to mask the herb's odor. Efficacy was analyzed using Mixed Models for Repeated Measures (MMRM). Of 150 participants, 138 completed the study. Both Ashwagandha (Mean HAM-A reduction -14.2) and Sertraline (-15.1) demonstrated statistical superiority over Placebo (-5.4; p < 0.001). The difference between active arms was not statistically significant, supporting comparable efficacy. Ashwagandha significantly reduced serum cortisol (-24.3%) and improved GAD-7 scores. Crucially, while Sertraline induced significant sexual dysfunction (worsened ASEX scores, p < 0.001) and nausea (28%), Ashwagandha showed a safety profile indistinguishable from placebo. In conclusion, standardized Withania somnifera extract (600 mg/day) offers anxiolytic efficacy comparable to Sertraline (50 mg/day) with a superior safety profile, specifically devoid of sexual and gastrointestinal adverse effects.
Quantitative Mapping of Phytochemical Synergy in Psidium guajava and Piper betle for Antidiarrheal Therapy: A Systematic Review and Meta-Analysis Using Radar Chart Analysis and AUC Kintoko; Cendekiawan, Khrisna Agung; Sapto Yuliani; Firdha Aprillia Wardhani
Eureka Herba Indonesia Vol. 7 No. 1 (2026): Eureka Herba Indonesia
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/ehi.v7i1.133

Abstract

Infectious diarrhea constitutes a massive global health burden defined by severe gastrointestinal hypermotility, profound fluid hypersecretion, and aggressive mucosal inflammation. Conventional pharmacotherapy, including antimotility agents and broad-spectrum antibiotics, presents significant clinical limitations, including the exacerbation of antimicrobial resistance and adverse systemic effects. Phytochemical interventions utilizing Psidium guajava and Piper betle offer a robust complementary approach. However, the exact quantitative magnitude of their combined pharmacological synergy requires rigorous statistical integration. A systematic review and meta-analysis were executed utilizing PRISMA protocols. Comprehensive literature screening across major databases identified primary research manuscripts reporting precise quantitative parameters on the antidiarrheal, antimicrobial, and antioxidant properties of the targeted extracts. Extracted data variables included sample sizes, mean outcomes, and standard deviations. The Standardized Mean Difference (SMD) and 95% Confidence Intervals (CI) were calculated using a random-effects model. The multidimensional therapeutic capacity was further mapped and quantified using Radar Chart Analysis (RCA) and geometric Area Under Curve (AUC) mathematical integration. The statistical synthesis indicated that Psidium guajava profoundly suppressed gastrointestinal motility and intestinal fluid accumulation (Pooled SMD = -2.45; 95% CI: -3.10 to -1.80). Concurrently, Piper betle demonstrated immense broad-spectrum bactericidal activity and superlative free radical scavenging capacity (Pooled SMD = 3.85; 95% CI: 2.95 to 4.75). The subsequent AUC integration revealed that combining the specific phytochemical profiles of both botanical sources mathematically expanded the total therapeutic coverage by 42%. The quantitative framework confirms a highly potent synergistic mechanism. Psidium guajava selectively targets the physiological symptoms of hypermotility and secretory failure, while Piper betle aggressively eradicates the underlying pathogenic etiology and neutralizes oxidative tissue damage. This dual-action synergy provides a formidable, evidence-based foundation for the development of advanced botanical therapeutics.

Page 11 of 11 | Total Record : 106

 7   8   9   10   11 

Filter by Year

2020 2026


Reset
Filter By Issues
All Issue Vol. 7 No. 1 (2026): Eureka Herba Indonesia Vol. 6 No. 2 (2025): Eureka Herba Indonesia Vol. 6 No. 1 (2025): Eureka Herba Indonesia Vol. 5 No. 3 (2024): Eureka Herba Indonesia Vol. 5 No. 2 (2024): Eureka Herba Indonesia Vol. 5 No. 1 (2024): Eureka Herba Indonesia Vol. 4 No. 4 (2023): Eureka Herba Indonesia Vol. 4 No. 3 (2023): Eureka Herba Indonesia Vol. 4 No. 2 (2023): Eureka Herba Indonesia Vol. 4 No. 1 (2023): Eureka Herba Indonesia Vol. 3 No. 2 (2022): Eureka Herba Indonesia Vol. 3 No. 1 (2022): Eureka Herba Indonesia Vol. 2 No. 2 (2021): Eureka Herba Indonesia Vol. 2 No. 1 (2021): Eureka Herba Indonesia Vol. 1 No. 2 (2020): Eureka Herba Indonesia Vol. 1 No. 1 (2020): Eureka Herba Indonesia More Issue